2019
DOI: 10.33594/000000074
|View full text |Cite
|
Sign up to set email alerts
|

Signalling Effects Induced by Acid Ceramidase in Human Epithelial Or Leukemic Cell Lines

Abstract: This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 31 publications
(81 reference statements)
0
1
0
Order By: Relevance
“…More recently, exogenous application of acid ceramidase was found to cause Akt kinase activation in Jurkat cells, and, however, affected their expansion. The latter was suggested to relate to the inability of the added ceramidase to promote activation of sphingosine kinase and, thereby, production of S1P in this system (Baduva et al, 2019). The ability of this particular bioactive sphingolipid to substantially regulate survival, trafficking, and activity of immune cells including T cells is well established, and with FTY720, a drug targeting S1P activity is in clinical use.…”
Section: Sphingomyelinases Take Part In But Are Not the Sole Players mentioning
confidence: 99%
“…More recently, exogenous application of acid ceramidase was found to cause Akt kinase activation in Jurkat cells, and, however, affected their expansion. The latter was suggested to relate to the inability of the added ceramidase to promote activation of sphingosine kinase and, thereby, production of S1P in this system (Baduva et al, 2019). The ability of this particular bioactive sphingolipid to substantially regulate survival, trafficking, and activity of immune cells including T cells is well established, and with FTY720, a drug targeting S1P activity is in clinical use.…”
Section: Sphingomyelinases Take Part In But Are Not the Sole Players mentioning
confidence: 99%